St. John's wort on the balance of benefit and risk. Important new information on efficacy and safety;Belangrijke nieuwe informatie over werkzaamheid en veiligheid. Sint- janskruid op de balans van werking en interacties

Pharmaceutisch Weekblad

Volumn 135, Issue 13, 2000, Pages 455-462

  De Smet, P A G M ^a   Touw, D J ^a  

^a NONE

Author keywords

Depression; Drug interactions; Efficacy; Hypericuni perforatum

Indexed keywords

AMITRIPTYLINE; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIVIRUS AGENT; ASTEMIZOLE; CALCIUM ANTAGONIST; CARBAMAZEPINE; CLOZAPINE; CORTICOSTEROID; CYCLOSPORIN; DIGOXIN; ETHINYLESTRADIOL; FLUOXETINE; HYPERFORIN; HYPERICIN; IMIPRAMINE; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; NEUROLEPTIC AGENT; PHENPROCOUMON; SEROTONIN UPTAKE INHIBITOR; TACROLIMUS; THEOPHYLLINE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; WARFARIN;

CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; HERBAL MEDICINE; HUMAN; HYPERICUM PERFORATUM; MAJOR CLINICAL STUDY; MENTAL DISEASE; PSYCHOPHARMACOTHERAPY; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

EID: 0034737478     PISSN: 00316911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. BMJ 1999;319:1534-8.
2. Ernst E. Second thoughts about safety of St John's wort. Lancet 1999;354:2014-6.
3. Linde K, Ramirez G, Mulrow CD, et al. St John's wort for depression - an overview and meta-analysis of randomised clinical trials. BMJ 1996;313:253-8.
4. De Smet PA, Nolen WA. St John's wort as an antidepressant [editorial; commentaar]. BMJ 1996;313:241-2.
5. Van der Kuy A, red. Farmacotherapeutisch Kompas 1999. Amstelveen: Ziekenfondsraad, 1999:121-2.
6. Wheatley D, LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients - a controlled 6-week clinical trial, Pharmacopsychiatry 1997,30 suppl 2:77-80.
7. Vorbach EU, Arnoldt KH, Hubner WD. Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry 1997;30 suppl 2:81-5
8. Harrer G, Schmidt U, Kuhn U, et al Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine. Arzneimittelforschung 1999;49:289-96.
9. Laakmann G, Schule C, Baghai T, et al. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 1998;31 suppl 1:54-9.
10. Lenoir S, Degenring FH, Saller R. A double-blind randomised trial to investigate three different concentrations of a standardised fresh plant extract obtained from the shoot tips of Hypericum perforatum L Phytomedicine 1999; 6:141-6.
11. Linde K, Berner M. Has hypericum found its place in antidepressant treatment? [commentaar]. BMJ 1999;319:1539.
12. Hūbner WD, Kalb R, Arnoldt KH. Multizentrische Studie zur Langzeitwirkung und Vertrāglichkeit des Johanniskraut-Extraktes LI 160 über 12 Monate, 10 Jahres-Tagung Gesellschaft fūr Phytotnerapie 11-13 November 1999, Münster 1999.
13. Nahrstedt A, Butterweck V. Biologically active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry 1997;30 suppl 2.129-34.
14. +. J Pharmacol Exp Ther 1999;290:1363-8.
15. Bon S, Hartmann K, Kuhn M. Johanniskraut: ein Enzyminduktor? Schweiz Ap Ztg 1999;16:535-6.
16. Golsch S, Vocks E, Rakoski J, et al. Reversible Erhohung der Photosensitivitāt im UV-B-Bereich durch Johanniskrautextrakt-Präparate. Hautarzt 1997;48:249-52.
17. Bove GM. Acute neuropathy after exposure to sun in a patient treated with St John's wort. Lancet 1998;352:1121-2.
18. Moses EL Mallinger AG, St. John's wort: three cases of possible mania induction. J Clin Psychopharmacol 2000;20:115-7.
19. Gordon JB. SSRIs and St. John's wort: possible toxicity? Am Fam Physician 1998;57:950, 953.
20. Lantz MS, Buchalter E, Giambanco V. St. John's wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol 1999;12:7-10.
21. Hansten PD, Horn JR. Drug interactions analysis and management. St Louis: Facts And Comparisons, 1999:523-7, N123-6.
22. Roots I, Johne A, Maurer A, et al. Pharmakokinetische Arzneimittel-Interaktionen unter der Behandlung mit Johanniskraut 10. Jahres-Tagung Gesellschaft für Phytotherapie 11-13 November 1999, Münster 1999.
23. Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St John's wort. Lancet 2000;355:547-8.
24. Nebel A, Schneider BJ, Baker RK, et al. Potential metabolic interaction between St. John's wort and theophylline. Ann Pharmacother 1999;33:502.
25. Johne A, Brockmoller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforotum). Clin Pharmacol Ther 1999;66:338-45.
26. Yue QY, Bergquist C, Gerden B. Safety of St John's wort (Hypericum perforatum). Lancet 2000;355:576-7.
27. Maurer A, Johne A, Bauer S, et al. Interaction of St. John's wort extract with phenprocoumon. Eur J Clin Pharmacol 1999;55:22.
28. Yue QY, Bergquist C. Johannesōrt kan ge oönskade interaktioner med mänga viktiga läkemedel. Weblocatie www.mpa.se/observanda/ obs99/johannesort.html. Geraadpleegd 1999 okt 27.
29. Rey JM, Walter G. Hypericum perforotum (St John's wort) in depression: pest or blessing? Med J Aust 1998;169:583-6.
30. Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to Saint John's wort Lancet 2000;355.548-9.
31. De Smet PAGM, Touw DJ. Safety of St John's wort (Hypericum perforatum). Lancet 2000;355:575-6.
32. Strayhorn VA, Baciewicz AM, Self TH. Update on rifampin drug interactions, III, Arch Intern Med 1997;157:2453-8.
33. Kerb R, Bauer S, Brockmoller J, et al. Urinary 6β-hydroxycortisol excretion rate is affected by treatment with hypericum extract. Eur J Clin Pharmacol 1997;52:A186.
34. Roby A, Kantor E, Anderson G, et al. St. Johns wort impact on CYP3A4 activity. NCDEV, 39th Annual Meeting, Boca Raton, Florida, June 1-4 1999.
35. Erehefsky B, Gewertz N, Lam F, et al. Determination of SJW differential metabolism at CYP2D6 and CYP3A4, using dextromethorphan probe methodology. NCDEV, 39th Annual Meeting, Boca Raton, Florida, June 1-4 1999.
36. Gewertz N, Erehefsky B, Lam F, et al. Determination of the differential effects of St-John's wort on the CYP1A2 and NAT2 metabolic pathways using caffeine probe methodology. NCDEV, 39th Annual Meeting, Boca Raton, Florida, June 1-4 1999.
37. Wheatley D. Safety of St John's wort (Hypericum perforotum). Lancet 2000;355:576.
38. Touw DJ, Breimer DD. Het cytochroom P450-enzymsysteem. Een familie met acties, reacties en interacties. Deel 1, Pharm Weekbl 1997;132:948-63.
39. Schepens MHJ, Franssen EJF. Een actieve pomp gereguleerd. De rol van P-glycoproteïne in de fysiologie en de farmacokinetiek. Pharm Weekbl 1999;134:230-4.
40. Chappey O, Scherrmann JM. La colchicine: données récentes sur sa pharmacocinétique et sa pharmacologie clinique. Rev Med Interne 1995;16:782-9.
41. Kovarik JM, Koelle EU. Cyclosporin pharmacokinetics in the elderly. Drugs Aging 1999;15:197-205.
42. Touw DJ, Breimer DD. Het cytochroom P450-enzymsysteem. Een familie met acties, reacties en interacties, Deel 2. Pharm Weekbl 1997;132:996-1009.
43. Nooijens H, Noort M. Medicatiebewaking van zelfzorg geïntroduceerd met nieuw project. "Gebruikt u nog andere geneesmiddelen? Vraag uw apotheker om advies". Pharm Weekbl 1998;133:1664-5.